Global microRNA Based Diagnostic Kit Market

microRNA Based Diagnostic Kit Comprehensive Study by Mode of Delivery (Conjugation, Virus-Associated Delivery, Nanoparticles), End Use (Hospitals and Clinics, Diagnostic Laboratories, Academic & Government Research Institutes), Therapeutic Area (Oncology, Hematology, Neurology, Others) Players and Region - Global Market Outlook to 2028

microRNA Based Diagnostic Kit Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About microRNA Based Diagnostic Kit
microRNA are small single-stranded RNA molecules that regulate 10–30% of all protein-coding genes. Major attributable factors in the microRNA-based diagnostic kit market include the increasing application of microRNA (miRNA) tools to diagnose neoplastic and non-neoplastic diseases and a rise in the adoption of miRNAs for target prediction, identification, and visualization. In addition, the use of microRNA signatures as potential biomarkers for patient management and increasing innovation and technological advances for detecting microRNAs in tissue and bodily fluids is driving the market growth during the forecast period.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The key players are highly focused on developing and innovating new strategies such as product launches and increased R&D to maintain their market position and customer base. The companies are also planning strategic activities like partnerships, collaboration, mergers, and acquisitions to help them sustain themselves in the market and maintain their competitive edge. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global microRNA Based Diagnostic Kit market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

TAmiRNA (Austria), Agilent Technologies (United States), Thermo Fisher Scientific Inc. (United States), Qiagen (Netherlands), Merck KGaA (Germany), NanoString (United States), HTG Molecular Diagnostics, Inc. (United States), Horizon Discovery Ltd. (United Kingdom), GeneCopoeia, Inc. (United States) and Takara Bio Inc (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are BioGenex (United States), Sistemic Scotland Limited (United States), Biodynamics Laboratory, Inc. (Greece) and Miltenyi Biotec (Germany).

Segmentation Overview
AMA Research has segmented the market of Global microRNA Based Diagnostic Kit market by and Region.



On the basis of geography, the market of microRNA Based Diagnostic Kit has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Mode of Delivery, the sub-segment i.e. Conjugation will boost the microRNA Based Diagnostic Kit market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End Use, the sub-segment i.e. Hospitals and Clinics will boost the microRNA Based Diagnostic Kit market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapeutic Area, the sub-segment i.e. Oncology will boost the microRNA Based Diagnostic Kit market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The surge in Prevalence of Cancer Patients

Market Growth Drivers:
Rising Incidence of Chronic Diseases such as Cancer, Rising Investments in miRNA Research & Development Initiatives and Favorable Government Initiatives and Increased Healthcare Expenditure

Challenges:
Challenges in Handling RNA & In-House Development of microRNA Assays

Restraints:
High cost associated with microRNA kits and other products

Opportunities:
Increasing Demand for Diagnostic Testing in Hospitals

Market Leaders and their expansionary development strategies
In January 2023, Thermo Fisher Scientific Inc. completed the acquisition of The Binding Site Group, a UK-based specialist diagnostic products provider for USD 2.8 billion in cash. The Binding Site offers specialty diagnostic assays and instruments that aid in the improvement of the diagnosis and management of blood cancers and immune system disorders.
In January 2023, Qiagen launched EZ2 Connect MDx for use in diagnostic laboratories. This launch enhanced the IVD platform to carry out automated sample processing for wide-scale use. The EZ2 Connect MDx enables laboratories to purify DNA and RNA from about 24 samples in parallel in mere 30 minutes.

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Mode of Delivery
  • Conjugation
  • Virus-Associated Delivery
  • Nanoparticles

By End Use
  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Academic & Government Research Institutes

By Therapeutic Area
  • Oncology
  • Hematology
  • Neurology
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidence of Chronic Diseases such as Cancer
      • 3.2.2. Rising Investments in miRNA Research & Development Initiatives
      • 3.2.3. Favorable Government Initiatives and Increased Healthcare Expenditure
    • 3.3. Market Challenges
      • 3.3.1. Challenges in Handling RNA & In-House Development of microRNA Assays
    • 3.4. Market Trends
      • 3.4.1. The surge in Prevalence of Cancer Patients
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global microRNA Based Diagnostic Kit, by Mode of Delivery, End Use, Therapeutic Area and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global microRNA Based Diagnostic Kit (Value)
      • 5.2.1. Global microRNA Based Diagnostic Kit by: Mode of Delivery (Value)
        • 5.2.1.1. Conjugation
        • 5.2.1.2. Virus-Associated Delivery
        • 5.2.1.3. Nanoparticles
      • 5.2.2. Global microRNA Based Diagnostic Kit by: End Use (Value)
        • 5.2.2.1. Hospitals and Clinics
        • 5.2.2.2. Diagnostic Laboratories
        • 5.2.2.3. Academic & Government Research Institutes
      • 5.2.3. Global microRNA Based Diagnostic Kit by: Therapeutic Area (Value)
        • 5.2.3.1. Oncology
        • 5.2.3.2. Hematology
        • 5.2.3.3. Neurology
        • 5.2.3.4. Others
      • 5.2.4. Global microRNA Based Diagnostic Kit Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global microRNA Based Diagnostic Kit (Price)
  • 6. microRNA Based Diagnostic Kit: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. TAmiRNA (Austria)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Agilent Technologies (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Qiagen (Netherlands)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck KGaA (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. NanoString (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. HTG Molecular Diagnostics, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Horizon Discovery Ltd. (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GeneCopoeia, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Takara Bio Inc (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global microRNA Based Diagnostic Kit Sale, by Mode of Delivery, End Use, Therapeutic Area and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global microRNA Based Diagnostic Kit (Value)
      • 7.2.1. Global microRNA Based Diagnostic Kit by: Mode of Delivery (Value)
        • 7.2.1.1. Conjugation
        • 7.2.1.2. Virus-Associated Delivery
        • 7.2.1.3. Nanoparticles
      • 7.2.2. Global microRNA Based Diagnostic Kit by: End Use (Value)
        • 7.2.2.1. Hospitals and Clinics
        • 7.2.2.2. Diagnostic Laboratories
        • 7.2.2.3. Academic & Government Research Institutes
      • 7.2.3. Global microRNA Based Diagnostic Kit by: Therapeutic Area (Value)
        • 7.2.3.1. Oncology
        • 7.2.3.2. Hematology
        • 7.2.3.3. Neurology
        • 7.2.3.4. Others
      • 7.2.4. Global microRNA Based Diagnostic Kit Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global microRNA Based Diagnostic Kit (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. microRNA Based Diagnostic Kit: by Mode of Delivery(USD Million)
  • Table 2. microRNA Based Diagnostic Kit Conjugation , by Region USD Million (2017-2022)
  • Table 3. microRNA Based Diagnostic Kit Virus-Associated Delivery , by Region USD Million (2017-2022)
  • Table 4. microRNA Based Diagnostic Kit Nanoparticles , by Region USD Million (2017-2022)
  • Table 5. microRNA Based Diagnostic Kit: by End Use(USD Million)
  • Table 6. microRNA Based Diagnostic Kit Hospitals and Clinics , by Region USD Million (2017-2022)
  • Table 7. microRNA Based Diagnostic Kit Diagnostic Laboratories , by Region USD Million (2017-2022)
  • Table 8. microRNA Based Diagnostic Kit Academic & Government Research Institutes , by Region USD Million (2017-2022)
  • Table 9. microRNA Based Diagnostic Kit: by Therapeutic Area(USD Million)
  • Table 10. microRNA Based Diagnostic Kit Oncology , by Region USD Million (2017-2022)
  • Table 11. microRNA Based Diagnostic Kit Hematology , by Region USD Million (2017-2022)
  • Table 12. microRNA Based Diagnostic Kit Neurology , by Region USD Million (2017-2022)
  • Table 13. microRNA Based Diagnostic Kit Others , by Region USD Million (2017-2022)
  • Table 14. South America microRNA Based Diagnostic Kit, by Country USD Million (2017-2022)
  • Table 15. South America microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 16. South America microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 17. South America microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 18. Brazil microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 19. Brazil microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 20. Brazil microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 21. Argentina microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 22. Argentina microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 23. Argentina microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 24. Rest of South America microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 25. Rest of South America microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 26. Rest of South America microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 27. Asia Pacific microRNA Based Diagnostic Kit, by Country USD Million (2017-2022)
  • Table 28. Asia Pacific microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 29. Asia Pacific microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 30. Asia Pacific microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 31. China microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 32. China microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 33. China microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 34. Japan microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 35. Japan microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 36. Japan microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 37. India microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 38. India microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 39. India microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 40. South Korea microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 41. South Korea microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 42. South Korea microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 43. Taiwan microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 44. Taiwan microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 45. Taiwan microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 46. Australia microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 47. Australia microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 48. Australia microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 49. Rest of Asia-Pacific microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 52. Europe microRNA Based Diagnostic Kit, by Country USD Million (2017-2022)
  • Table 53. Europe microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 54. Europe microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 55. Europe microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 56. Germany microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 57. Germany microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 58. Germany microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 59. France microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 60. France microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 61. France microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 62. Italy microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 63. Italy microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 64. Italy microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 65. United Kingdom microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 66. United Kingdom microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 67. United Kingdom microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 68. Netherlands microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 69. Netherlands microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 70. Netherlands microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 71. Rest of Europe microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 72. Rest of Europe microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 73. Rest of Europe microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 74. MEA microRNA Based Diagnostic Kit, by Country USD Million (2017-2022)
  • Table 75. MEA microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 76. MEA microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 77. MEA microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 78. Middle East microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 79. Middle East microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 80. Middle East microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 81. Africa microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 82. Africa microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 83. Africa microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 84. North America microRNA Based Diagnostic Kit, by Country USD Million (2017-2022)
  • Table 85. North America microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 86. North America microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 87. North America microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 88. United States microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 89. United States microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 90. United States microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 91. Canada microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 92. Canada microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 93. Canada microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 94. Mexico microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2017-2022)
  • Table 95. Mexico microRNA Based Diagnostic Kit, by End Use USD Million (2017-2022)
  • Table 96. Mexico microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2017-2022)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. microRNA Based Diagnostic Kit: by Mode of Delivery(USD Million)
  • Table 108. microRNA Based Diagnostic Kit Conjugation , by Region USD Million (2023-2028)
  • Table 109. microRNA Based Diagnostic Kit Virus-Associated Delivery , by Region USD Million (2023-2028)
  • Table 110. microRNA Based Diagnostic Kit Nanoparticles , by Region USD Million (2023-2028)
  • Table 111. microRNA Based Diagnostic Kit: by End Use(USD Million)
  • Table 112. microRNA Based Diagnostic Kit Hospitals and Clinics , by Region USD Million (2023-2028)
  • Table 113. microRNA Based Diagnostic Kit Diagnostic Laboratories , by Region USD Million (2023-2028)
  • Table 114. microRNA Based Diagnostic Kit Academic & Government Research Institutes , by Region USD Million (2023-2028)
  • Table 115. microRNA Based Diagnostic Kit: by Therapeutic Area(USD Million)
  • Table 116. microRNA Based Diagnostic Kit Oncology , by Region USD Million (2023-2028)
  • Table 117. microRNA Based Diagnostic Kit Hematology , by Region USD Million (2023-2028)
  • Table 118. microRNA Based Diagnostic Kit Neurology , by Region USD Million (2023-2028)
  • Table 119. microRNA Based Diagnostic Kit Others , by Region USD Million (2023-2028)
  • Table 120. South America microRNA Based Diagnostic Kit, by Country USD Million (2023-2028)
  • Table 121. South America microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 122. South America microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 123. South America microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 124. Brazil microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 125. Brazil microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 126. Brazil microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 127. Argentina microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 128. Argentina microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 129. Argentina microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 130. Rest of South America microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 131. Rest of South America microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 132. Rest of South America microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 133. Asia Pacific microRNA Based Diagnostic Kit, by Country USD Million (2023-2028)
  • Table 134. Asia Pacific microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 135. Asia Pacific microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 136. Asia Pacific microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 137. China microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 138. China microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 139. China microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 140. Japan microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 141. Japan microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 142. Japan microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 143. India microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 144. India microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 145. India microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 146. South Korea microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 147. South Korea microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 148. South Korea microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 149. Taiwan microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 150. Taiwan microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 151. Taiwan microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 152. Australia microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 153. Australia microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 154. Australia microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 155. Rest of Asia-Pacific microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 156. Rest of Asia-Pacific microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 157. Rest of Asia-Pacific microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 158. Europe microRNA Based Diagnostic Kit, by Country USD Million (2023-2028)
  • Table 159. Europe microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 160. Europe microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 161. Europe microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 162. Germany microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 163. Germany microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 164. Germany microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 165. France microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 166. France microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 167. France microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 168. Italy microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 169. Italy microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 170. Italy microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 171. United Kingdom microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 172. United Kingdom microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 173. United Kingdom microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 174. Netherlands microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 175. Netherlands microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 176. Netherlands microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 177. Rest of Europe microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 178. Rest of Europe microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 179. Rest of Europe microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 180. MEA microRNA Based Diagnostic Kit, by Country USD Million (2023-2028)
  • Table 181. MEA microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 182. MEA microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 183. MEA microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 184. Middle East microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 185. Middle East microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 186. Middle East microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 187. Africa microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 188. Africa microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 189. Africa microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 190. North America microRNA Based Diagnostic Kit, by Country USD Million (2023-2028)
  • Table 191. North America microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 192. North America microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 193. North America microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 194. United States microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 195. United States microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 196. United States microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 197. Canada microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 198. Canada microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 199. Canada microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 200. Mexico microRNA Based Diagnostic Kit, by Mode of Delivery USD Million (2023-2028)
  • Table 201. Mexico microRNA Based Diagnostic Kit, by End Use USD Million (2023-2028)
  • Table 202. Mexico microRNA Based Diagnostic Kit, by Therapeutic Area USD Million (2023-2028)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global microRNA Based Diagnostic Kit: by Mode of Delivery USD Million (2017-2022)
  • Figure 5. Global microRNA Based Diagnostic Kit: by End Use USD Million (2017-2022)
  • Figure 6. Global microRNA Based Diagnostic Kit: by Therapeutic Area USD Million (2017-2022)
  • Figure 7. South America microRNA Based Diagnostic Kit Share (%), by Country
  • Figure 8. Asia Pacific microRNA Based Diagnostic Kit Share (%), by Country
  • Figure 9. Europe microRNA Based Diagnostic Kit Share (%), by Country
  • Figure 10. MEA microRNA Based Diagnostic Kit Share (%), by Country
  • Figure 11. North America microRNA Based Diagnostic Kit Share (%), by Country
  • Figure 12. Global microRNA Based Diagnostic Kit share by Players 2022 (%)
  • Figure 13. Global microRNA Based Diagnostic Kit share by Players (Top 3) 2022(%)
  • Figure 14. Global microRNA Based Diagnostic Kit share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. TAmiRNA (Austria) Revenue, Net Income and Gross profit
  • Figure 17. TAmiRNA (Austria) Revenue: by Geography 2022
  • Figure 18. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 19. Agilent Technologies (United States) Revenue: by Geography 2022
  • Figure 20. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2022
  • Figure 22. Qiagen (Netherlands) Revenue, Net Income and Gross profit
  • Figure 23. Qiagen (Netherlands) Revenue: by Geography 2022
  • Figure 24. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Merck KGaA (Germany) Revenue: by Geography 2022
  • Figure 26. NanoString (United States) Revenue, Net Income and Gross profit
  • Figure 27. NanoString (United States) Revenue: by Geography 2022
  • Figure 28. HTG Molecular Diagnostics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. HTG Molecular Diagnostics, Inc. (United States) Revenue: by Geography 2022
  • Figure 30. Horizon Discovery Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Horizon Discovery Ltd. (United Kingdom) Revenue: by Geography 2022
  • Figure 32. GeneCopoeia, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. GeneCopoeia, Inc. (United States) Revenue: by Geography 2022
  • Figure 34. Takara Bio Inc (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Takara Bio Inc (Japan) Revenue: by Geography 2022
  • Figure 36. Global microRNA Based Diagnostic Kit: by Mode of Delivery USD Million (2023-2028)
  • Figure 37. Global microRNA Based Diagnostic Kit: by End Use USD Million (2023-2028)
  • Figure 38. Global microRNA Based Diagnostic Kit: by Therapeutic Area USD Million (2023-2028)
  • Figure 39. South America microRNA Based Diagnostic Kit Share (%), by Country
  • Figure 40. Asia Pacific microRNA Based Diagnostic Kit Share (%), by Country
  • Figure 41. Europe microRNA Based Diagnostic Kit Share (%), by Country
  • Figure 42. MEA microRNA Based Diagnostic Kit Share (%), by Country
  • Figure 43. North America microRNA Based Diagnostic Kit Share (%), by Country
List of companies from research coverage that are profiled in the study
  • TAmiRNA (Austria)
  • Agilent Technologies (United States)
  • Thermo Fisher Scientific Inc. (United States)
  • Qiagen (Netherlands)
  • Merck KGaA (Germany)
  • NanoString (United States)
  • HTG Molecular Diagnostics, Inc. (United States)
  • Horizon Discovery Ltd. (United Kingdom)
  • GeneCopoeia, Inc. (United States)
  • Takara Bio Inc (Japan)
Additional players considered in the study are as follows:
BioGenex (United States) , Sistemic Scotland Limited (United States) , Biodynamics Laboratory, Inc. (Greece) , Miltenyi Biotec (Germany)
Select User Access Type

Key Highlights of Report


Feb 2023 203 Pages 53 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global microRNA Based Diagnostic Kit Market Quantitative research analysis
Global microRNA Based Diagnostic Kit Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as TAmiRNA (Austria), Agilent Technologies (United States), Thermo Fisher Scientific Inc. (United States), Qiagen (Netherlands), Merck KGaA (Germany), NanoString (United States), HTG Molecular Diagnostics, Inc. (United States), Horizon Discovery Ltd. (United Kingdom), GeneCopoeia, Inc. (United States) and Takara Bio Inc (Japan) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"The surge in Prevalence of Cancer Patients" is seen as one of major influencing trends for microRNA Based Diagnostic Kit Market during projected period 2022-2028.
The microRNA Based Diagnostic Kit market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global microRNA Based Diagnostic Kit Market Report?

Have a Query? Click Here

Other Related Reports

Azadirachtin- Comprehensive Study by Application (Insecticides, Nematicides, Pesticides, Other), BY form (Liquid, Powder), BY End Use (Agriculture, Animal Husbandry, Horticulture, Cosmetics, Food & ...
$ 3800
Waste To Energy Technology Comprehensive Study by Type (Thermal, Thermo-Chemical, Mechanical-Thermal, Biochemical), Application (Heat, Fuels, Electricity), By Material (Cellulosic, Organic material),...
$ 3800
Hydrosols Comprehensive Study by Type (Organic, Conventional), Application (Perfumes, Skin Toners, Makeup, Aromatherapy, Alternative Medicines, Others), Distribution channel (Hypermarket & Supermark...
$ 3800
Biopharma Plastics Comprehensive Study by Application (Syringe, Gloves and masks, Depth filter, Containers, Others), Types (Polyethylene, Polypropylene, Polyvinyl chloride, Polyethylene terephthalate...
$ 3800
PFAS Testing Comprehensive Study by Application (Food Packaging, Water Samples, Foam Products, Textiles, Others), PFAS Type (Perfluorooctanoic acid (PFOA), Perfluorooctane sulfonic acid (PFOS), Perfl...
$ 3800
Microbial Fermentation Comprehensive Study by Type (Enzymes, Organic Acids, Vitamins, Amino Acids, Others), Application (Pharmaceutical, Food & Beverages, Industrial Chemical, Agricultural, Others), ...
$ 3800